LIPOSYN 10%
LOE ApproachingNDAINJECTIONINJECTABLE
Approved
May 1979
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 4d ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
LIPOSYN 10% is an injectable lipid emulsion approved in 1979 for parenteral nutrition support. The product provides essential fatty acids and calories to patients unable to consume nutrition orally or enterally. It is a small molecule lipid formulation administered intravenously as part of total parenteral nutrition (TPN) regimens.
LOE Approaching
Product approaching loss of exclusivity with moderate competitive pressure (30); team likely focused on defending market share and managing transition to generic competition.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on LIPOSYN 10% offers experience in hospital-based specialty pharmaceutical sales, formulary management, and mature product defense in a commodity-like market. This role emphasizes relationship-based selling, cost containment, and account retention rather than market expansion or innovation.
Account ManagerHospital Sales Representative
Worked on LIPOSYN 10% at Abbott? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.